Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma

BACKGROUND. Immune checkpoint inhibitors, along with BRAF and MEK inhibitors, have dramatically changed the management of and outlook for patients with metastatic melanoma. Analyses of long‐term follow‐up data and subanalyses based on disease characteristics may inform clinical decision making. METH...

Descripción completa

Detalles Bibliográficos
Autor principal: Luke, Jason J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Melanoma and Cutaneous Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853121/
https://www.ncbi.nlm.nih.gov/pubmed/31064886
http://dx.doi.org/10.1634/theoncologist.2018-0876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853121/
https://www.ncbi.nlm.nih.gov/pubmed/31064886
http://dx.doi.org/10.1634/theoncologist.2018-0876

Ejemplares similares